2,869 reports of this reaction
1.8% of all METOCLOPRAMIDE reports
#10 most reported adverse reaction
MOVEMENT DISORDER is the #10 most commonly reported adverse reaction for METOCLOPRAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 2,869 FDA adverse event reports linking METOCLOPRAMIDE to MOVEMENT DISORDER. This represents approximately 1.8% of all 156,854 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE who experience movement disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOVEMENT DISORDER is a less commonly reported adverse event for METOCLOPRAMIDE, but still significant enough to appear in the safety profile.
In addition to movement disorder, the following adverse reactions have been reported for METOCLOPRAMIDE:
The following drugs have also been linked to movement disorder in FDA adverse event reports:
MOVEMENT DISORDER has been reported as an adverse event in 2,869 FDA reports for METOCLOPRAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOVEMENT DISORDER accounts for approximately 1.8% of all adverse event reports for METOCLOPRAMIDE, making it a notable side effect.
If you experience movement disorder while taking METOCLOPRAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.